Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS).

Literature DB >> 19013651

Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS).

Rongzhen Zhang¹, Robert G Miller, Ron Gascon, Stacey Champion, Jonathan Katz, Mariselle Lancero, Amy Narvaez, Ronald Honrada, David Ruvalcaba, Michael S McGrath.

Abstract

The present study reports elevated levels of endotoxin/lipopolysaccharide (LPS) concentrations in plasma from patients with sporadic amyotrophic lateral sclerosis (sALS) and Alzheimer's (AD) as compared to healthy controls. Levels of plasma LPS showed a significant positive correlation with degree of blood monocyte/macrophage activation in disease groups and was most elevated in patients with advanced sALS disease. There was a significant negative relationship between plasma LPS and levels of monocyte/macrophage IL-10 expression in sALS blood. These data suggest that systemic LPS levels and activated monocyte/macrophages may play significant roles in the pathogenesis of sALS.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2008 PMID： 19013651 PMCID： PMC2995297 DOI： 10.1016/j.jneuroim.2008.09.017

Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478

33 in total

1. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide.

Authors: T H Flo; O Halaas; E Lien; L Ryan; G Teti; D T Golenbock; A Sundan; T Espevik
Journal: J Immunol Date: 2000-02-15 Impact factor: 5.422

2. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis.

Authors: S Ono; J Hu; N Shimizu; T Imai; H Nakagawa
Journal: J Neurol Sci Date: 2001-06-15 Impact factor: 3.181

3. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors: J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal: J Neurol Sci Date: 1999-10-31 Impact factor: 3.181

4. Immune reactivity in a mouse model of familial ALS correlates with disease progression.

Authors: M E Alexianu; M Kozovska; S H Appel
Journal: Neurology Date: 2001-10-09 Impact factor: 9.910

5. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis.

Authors: M Poloni; D Facchetti; R Mai; A Micheli; L Agnoletti; G Francolini; G Mora; C Camana; L Mazzini; T Bachetti
Journal: Neurosci Lett Date: 2000-06-30 Impact factor: 3.046

6. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration.

Authors: H Wilms; J Sievers; R Dengler; J Bufler; G Deuschl; R Lucius
Journal: J Neuroimmunol Date: 2003-11 Impact factor: 3.478

7. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.

Authors: Jenny S Henkel; Joseph I Engelhardt; László Siklós; Ericka P Simpson; Seung H Kim; Tianhong Pan; J Clay Goodman; Teepu Siddique; David R Beers; Stanley H Appel
Journal: Ann Neurol Date: 2004-02 Impact factor: 10.422

Review 8. Inflammatory processes in amyotrophic lateral sclerosis.

Authors: P L McGeer; E G McGeer
Journal: Muscle Nerve Date: 2002-10 Impact factor: 3.217

Review 9. Toll-like receptors.

Authors: Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal: Annu Rev Immunol Date: 2001-12-19 Impact factor: 28.527

10. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India.

Authors: G Nagesh Babu; Alok Kumar; Ramesh Chandra; S K Puri; Jayantee Kalita; U K Misra
Journal: Neurochem Res Date: 2008-02-02 Impact factor: 3.996

95 in total

1. Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B.

Authors: Sergio M de Almeida; Indianara Rotta; Yanxin Jiang; Xiao Li; Sonia M Raboni; Clea E Ribeiro; Davey Smith; Michael Potter; Florin Vaida; Scott Letendre; Ronald J Ellis
Journal: J Neurovirol Date: 2016-07-11 Impact factor: 2.643

Review 2. Curcumin-mediated regulation of intestinal barrier function: The mechanism underlying its beneficial effects.

Authors: Siddhartha S Ghosh; Hongliang He; Jing Wang; Todd W Gehr; Shobha Ghosh
Journal: Tissue Barriers Date: 2018-02-08

Review 3. Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.

Authors: Xin Fang
Journal: Metab Brain Dis Date: 2018-04-22 Impact factor: 3.584

Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS).

1. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide.

2. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis.

3. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

4. Immune reactivity in a mouse model of familial ALS correlates with disease progression.

5. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis.

6. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration.

7. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.

Review 8. Inflammatory processes in amyotrophic lateral sclerosis.

Review 9. Toll-like receptors.

10. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India.

1. Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B.

Review 2. Curcumin-mediated regulation of intestinal barrier function: The mechanism underlying its beneficial effects.

Review 3. Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.

Review 4. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Review 5. Leaky gut: mechanisms, measurement and clinical implications in humans.

Review 6. Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.

7. Systemic immune system alterations in early stages of Alzheimer's disease.

Review 8. Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Review 9. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection.

Review 10. The blood-brain barrier in neuroimmunology: Tales of separation and assimilation.